As the U.S. stock market navigates through a period of cautious optimism, with investors closely monitoring Federal Reserve developments and recent policy changes, attention turns to the potential within smaller-cap stocks. Penny stocks, although an older term, still represent an intriguing segment of the market where smaller or newer companies can provide unique opportunities for growth and value. By focusing on those with strong financials and clear growth paths, investors may uncover promising prospects among these under-the-radar firms.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.265 | $484.33M | ✅ 5 ⚠️ 0 View Analysis > |
| ATRenew (RERE) | $4.475 | $1B | ✅ 3 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.785 | $647.38M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $1.15 | $191.54M | ✅ 4 ⚠️ 2 View Analysis > |
| Puma Biotechnology (PBYI) | $4.99 | $264.45M | ✅ 3 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $2.005 | $23.87M | ✅ 4 ⚠️ 2 View Analysis > |
| Table Trac (TBTC) | $4.55 | $20.27M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.9423 | $6.81M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $4.00 | $90.86M | ✅ 3 ⚠️ 3 View Analysis > |
| Resources Connection (RGP) | $4.85 | $166.03M | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 385 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
OraSure Technologies (OSUR)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: OraSure Technologies, Inc. is a company that develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices globally with a market cap of $219.41 million.
Operations: The company's revenue is derived from its Diagnostics and Molecular Solutions segment, which generated $138.53 million.
Market Cap: $219.41M
OraSure Technologies, with a market cap of US$219.41 million, faces challenges typical of penny stocks, including recent financial losses and declining sales. For Q2 2025, the company reported revenues of US$31.24 million and a net loss of US$19.69 million compared to last year's figures. Despite being debt-free with strong asset coverage over liabilities (US$301.4M in short-term assets), OraSure remains unprofitable but has reduced losses by 11.3% annually over five years. Recent strategic moves include launching HEMAcollect™ PROTEIN for proteomic research and appointing Anne Messing as Chief Commercial Officer to drive growth initiatives amidst M&A interest from Ron Zwanziger.
- Unlock comprehensive insights into our analysis of OraSure Technologies stock in this financial health report.
- Review our growth performance report to gain insights into OraSure Technologies' future.
Prelude Therapeutics (PRLD)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $70.18 million.
Operations: Prelude Therapeutics does not report any revenue segments.
Market Cap: $70.18M
Prelude Therapeutics, with a market cap of US$70.18 million, is pre-revenue and faces typical challenges associated with penny stocks. The company reported a net loss of US$31.23 million for Q2 2025, slightly improved from the previous year. Despite being debt-free and having short-term assets exceeding liabilities (US$76.9M vs US$20.9M), Prelude's cash runway is less than a year if cash flow trends continue. Recent developments include an increase in authorized shares and the appointment of Dr. Paul Scherer to the board, highlighting strategic efforts to strengthen governance amidst ongoing financial pressures and high share price volatility.
- Jump into the full analysis health report here for a deeper understanding of Prelude Therapeutics.
- Examine Prelude Therapeutics' earnings growth report to understand how analysts expect it to perform.
Douglas Elliman (DOUG)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Douglas Elliman Inc. operates in the United States, providing real estate services and property technology investments, with a market cap of approximately $241.29 million.
Operations: The company's revenue is primarily generated from its Real Estate Brokerage segment, which accounts for $1.03 billion.
Market Cap: $241.29M
Douglas Elliman, with a market cap of US$241.29 million, faces challenges typical of penny stocks, including unprofitability and increasing losses over the past five years. Despite these hurdles, it has launched Elliman Capital to expand its mortgage services and enhance its real estate offerings. The company's short-term assets exceed liabilities (US$192.4M vs US$96.9M), providing some financial stability. Recent inclusion in multiple Russell indices may boost visibility among investors. However, long-term liabilities exceed short-term assets (US$254.5M vs US$192.4M), and earnings have declined significantly, underscoring ongoing financial difficulties amidst strategic expansions.
- Get an in-depth perspective on Douglas Elliman's performance by reading our balance sheet health report here.
- Gain insights into Douglas Elliman's historical outcomes by reviewing our past performance report.
Seize The Opportunity
- Explore the 385 names from our US Penny Stocks screener here.
- Contemplating Other Strategies? Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Douglas Elliman might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com